Targeting Liver <i>Xor</i> by GalNAc-siRNA Is an Effective Strategy for Hyperuricemia Therapy
Hyperuricemia, i.e., increased plasma uric acid concentration, is a common problem in clinical practice, leading to gout or nephrolithiasis, and is associated with other disorders, such as metabolic syndrome, cardiovascular disease, and chronic renal disease. Xanthine oxidoreductase (XOR) is a criti...
Saved in:
Main Authors: | Huiyan Sun (Author), Xinxia Wang (Author), Yongqiang Li (Author), Yingzhi Shen (Author), Lin Zhang (Author), Yingjie Xu (Author), Junling Liu (Author), Xuemei Fan (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
RAB18 is a key regulator of GalNAc-conjugated siRNA-induced silencing in Hep3B cells
by: Jiamiao Lu, et al.
Published: (2022) -
Lectin Histochemical Study of GalNac and GlcNac Containing Glycoconjugates in Colon Adenocarcinoma
by: Mohamad Reza Arab, et al.
Published: (2013) -
Evidence of gene conversion in genes encoding the Gal/GalNac lectin complex of Entamoeba.
by: Gareth D Weedall, et al.
Published: (2011) -
Targeting ANGPTL3 by GalNAc-conjugated siRNA ANGsiR10 lowers blood lipids with long-lasting and potent efficacy in mice and monkeys
by: Jue Wang, et al.
Published: (2023) -
Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics
by: Yuanyu Huang
Published: (2017)